Factors associated with HBV virological breakthrough

Antiviral Therapy

Volumn 22, Issue 1, 2017, Pages 53-60

  Sheppard Law, Suzanne ^a,b,c   Zablotska Manos, Iryna ^c   Kermeen, Melissa ^d   Holdaway, Susan ^e   Lee, Alice ^d   Zekry, Amany ^f,g   Dore, Gregory J ^c   George, Jacob ^e,h   Maher, Lisa ^c  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Department of Microbiology and Infectious Diseases   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f ST GEORGE HOSPITAL   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; CHINESE MEDICINE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG RESPONSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; RECEIVER OPERATING CHARACTERISTIC; SELF REPORT; BLOOD; CHRONIC HEPATITIS B; CLINICAL TRIAL; DRUG EFFECTS; EVIDENCE BASED MEDICINE; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; AUSTRALIA; CROSS-SECTIONAL STUDIES; DNA, VIRAL; EVIDENCE-BASED MEDICINE; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RISK FACTORS; SELF REPORT; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; VIRAL LOAD; YOUNG ADULT;

EID: 85015874305     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3087     Document Type: Article

References (44)

1. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 2008; 22:991-1008.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107.
3. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia annual surveillance report 2015. Sydney, Australia: The Kirby Institute, UNSW Australia 2015. (Accessed 1 February 2016.) Available from http://kirby.unsw.edu.au/surveillance/2015-annual-surveillance-report-hiv-viral-hepatitis-stis
4. Walter SR, Thein HH, Amin J, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol 2011; 54:879-886.
5. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127 Suppl 1:S35-S50.
6. Liaw YF. Chronic hepatitis B virus infection: spectrum, pathogenesis and natural history. In: Sarin SK, Okudo K (editors). Hepatitis B and C. New Delhi: Harcourt; 2002.
7. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-352.
8. Lok ASF. Hepatitis B. In: Dooley J, Lok A, Burroughs A, Heathcote J (editors). Sherlock's Diseases of the Liver and Biliary System. UK: Blackwell Publishing; 2011. p. 367-392.
9. Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int 2012; 32:1333-1341.
10. Suzuki Y, Suzuki F, Kawamura Y, et al. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance? J Gastroenterol Hepatol 2009; 24:429-435.
11. Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011; 53:1854-1863.
12. Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011; 66:2715-2725.
13. Wang J, Wang M, Huang Y. Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: a report of two cases. Scand J Infect Dis 2013; 45:158-160.
14. Lok A, McMahon B. AASLD Practice Guideline Update: Chronic hepatitis B. Hepatology 2009; 50:661-662.
15. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-185.
16. Gastroenterology Society of Australia. Australia and New Zealand Chronic HBV recommendations. Mulgrave, Victoria: Digestive Health Foundation, 2009/2010.
17. Liaw YF, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6:535-561.
18. Kamezaki H, Kanda T, Wu S, et al. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication. Scand J Gastroenterol 2011; 46:1111-1117.
19. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat 2012; 19:377-386.
20. Chotiyaputta W, Hongthanakorn K, Oberhelman R, et al. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. J Viral Hepat 2012; 19:205-212.
21. Batirel A, Guclu E, Arslan F, et al. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis 2014; 28:153-159.
22. Hilleret M, Larrat S, Stanke-Labesque F, Leroy V. Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough? J Hepat 2011; 55:1468-1469.
23. Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014; 59:434-442.
24. Kamezaki H, Kanda T, Arai M, et al. Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with lamivudine. Int J Med Sci 2013; 10:567-574.
25. Polis S, Zablotska-Manos I, Zekry A, Maher L. Adherence to hepatitis B anti-viral therapy: a qualitative study. Gastroenterol Nurs; in press.
26. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8:283-298.
27. O'Sullivan BG, Gidding HF, Law M, et al. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust N Z J Public Health 2004; 28:212-216.
28. Nguyen VTT, Razali K, Amin J, Law MG, Dore GJ. Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries. J Gastroenterol Hepatol 2008; 23:922-929.
29. MacLachlan JH, Allard N, Towell V, Cowie BC. The burden of chronic hepatitis B virus infection in Australia, 2011. Aust N Z J Public Health 2013; 37:416-422.
30. Cowie B. The linguistic demography of Australians living with chronic hepatitis B. Aust N Z J Public Health 2011; 35:12-15.
31. Yapali S, Talaat N, Lok AS. Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol 2014; 12:16-26.
32. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386:1546-1555.
33. Howell J, Van Gemert C, Lemoine M, Thursz M, Hellard M. An overview of hepatitis B prevalence, prevention, and management in the Pacific Islands and Territories. J Gastroenterol Hepatol 2014; 29:1854-1866.
34. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
35. Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 2011; 26 Suppl 1:138-143.
36. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51:422-430.
37. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140:132-143.
38. van Vlerken LG, Arends P, Lieveld FI, et al. Real life adherence of chronic hepatitis B patients to entecavir treatment. Dig Liver Dis 2015; 47:577-583.
39. Chotiyaputta W, Peterson C, Ditah F, Goodwin D, Lok A. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011; 54:12-18.
40. Giang L, Selinger CP, Lee AU. Evaluation of adherence to oral anti-viral hepatitis B treatment using structured questionnaires. World J Hepatol 2012; 4:43-49.
41. Sogni P, Carrieri MP, Fontaine H, et al. The role of adherence in virological suppression in patients receiving anti-HBV analogues. Antivir Ther 2012; 17:395-400.
42. Lieveld FI, Van vlerken LG, Siersema PD, Erpecum KJ. Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Ann Hepatol 2013; 12:380-391.
43. Lee M. Adherence with use of oral agents in the treatment of chronic hepatitis B. Curr Hepatol Rep 2012; 11:70-74.
44. Lim YS, Byun KS, Yoo BC, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut 2016; 65:852-860.